Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2014 Sep 12;9(9):e106748.
doi: 10.1371/journal.pone.0106748. eCollection 2014.

"V体育2025版" Discovery and validation of new potential biomarkers for early detection of colon cancer

Xavier Solé  1 , Marta Crous-Bou  1 , David Cordero  1 , David Olivares  1 , Elisabet Guinó  1 , Rebeca Sanz-Pamplona  1 , Francisco Rodriguez-Moranta  2 , Xavier Sanjuan  3 , Javier de Oca  4 , Ramon Salazar  5 , Victor Moreno  6
Affiliations

"VSports注册入口" Discovery and validation of new potential biomarkers for early detection of colon cancer

Xavier Solé (V体育平台登录) et al. PLoS One. .

Abstract

Background: Accurate detection of characteristic proteins secreted by colon cancer tumor cells in biological fluids could serve as a biomarker for the disease VSports手机版. The aim of the present study was to identify and validate new serum biomarkers and demonstrate their potential usefulness for early diagnosis of colon cancer. .

Methods: The study was organized in three sequential phases: 1) biomarker discovery, 2) technical and biological validation, and 3) proof of concept to test the potential clinical use of selected biomarkers V体育安卓版. A prioritized subset of the differentially-expressed genes between tissue types (50 colon mucosa from cancer-free individuals and 100 normal-tumor pairs from colon cancer patients) was validated and further tested in a series of serum samples from 80 colon cancer cases, 23 patients with adenoma and 77 cancer-free controls. .

Results: In the discovery phase, 505 unique candidate biomarkers were identified, with highly significant results and high capacity to discriminate between the different tissue types. After a subsequent prioritization, all tested genes (N = 23) were successfully validated in tissue, and one of them, COL10A1, showed relevant differences in serum protein levels between controls, patients with adenoma (p = 0. 0083) and colon cancer cases (p = 3 V体育ios版. 2e-6). .

Conclusion: We present a sequential process for the identification and further validation of biomarkers for early detection of colon cancer that identifies COL10A1 protein levels in serum as a potential diagnostic candidate to detect both adenoma lesions and tumor. VSports最新版本.

Impact: The use of a cheap serum test for colon cancer screening should improve its participation rates and contribute to decrease the burden of this disease. V体育平台登录.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have filed a patent regarding the use of COL10A1 as biomarker for early diagnosis of colon cancer with title: “SERUM BIOMARKER FOR DIAGNOSING COLORECTAL CANCER”. European patent number: EP2680003A1 (28. 06. 2012) and Spain ES2436667A2(03. 01. 2014) VSports注册入口. The authors confirm that this does not alter their adherence to all PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Differences in expression between tissue types in the biomarker discovery series.
A. Principal component analysis. B. Differentially expressed genes between adjacent normal and cancer-free samples. C. Differentially expressed genes between tumor and cancer-free samples.
Figure 2
Figure 2. Heatmap of threshold cycle values from technical (A) and biological validation (B).
Samples are color-coded on top of the heatmaps based on the tissue type (i.e., cancer-free mucosa = green, adjacent normal tissue from colon cancer patients = blue, tumor tissue = red).
Figure 3
Figure 3. ELISA serum concentrations of each selected protein in cancer-free controls, patients with adenoma and colon cancer cases.
Figure 4
Figure 4. COL10A1 performance as a diagnostic biomarker.
A. Receiver operating characteristic curves for both adenomas and colon cancer together (purple) and colon cancer cases only (red). B. Different marker cutpoints against the sensitivity and specificity curves.
See this image and copyright information in PMC

References

    1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765–781. - V体育官网入口 - PubMed
    1. Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008) Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB reports 41: 685–692. - PubMed (VSports app下载)
    1. Burt RW (2010) Colorectal cancer screening. Current opinion in gastroenterology 26: 466–470. - PubMed
    1. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, et al. (2013) European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 45: 51–59. - PMC - PubMed
    1. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, Nicolas D, Moreno SG, et al. (2010) Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. Journal of gastroenterology 45: 703–712. - PubMed (V体育2025版)

Publication types

MeSH terms